2. Signaling Pathways
  3. Anti-infection
  4. RABV

RABV

Rabies Virus

 

RABV Related Products (14):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-18980
    Rottlerin
    		Inhibitor 98.09%
    Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific PKC inhibitor, with IC50 values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM. Rottlerin acts as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1. Rottlerin induces apoptosis via caspase 3 activation. Rottlerin inhibits HIV-1 integration and Rabies virus (RABV) infection.
    Rottlerin
  • HY-P5623A1
    RVG-Cys acetate
    		99.78%
    RVG-Cys (RVG29-Cys;RDP-Cy) acetate is based on rabies virus glycoprotein (RVG29) peptide and connected to Cys to facilitate subsequent coupling.
    RVG-Cys acetate
  • HY-P4086
    Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R)
    		98.00%
    Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R), a chimeric peptide consisting of 29 amino acids, is synthesized by adding nona-arginine motif to the carboxy terminus of RVG (rabies virus glycoprotein). Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) is positively charged and able to bind negatively charged nucleic acids via charge interaction.
    Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R)
  • HY-133735A
    GRP-60367 hydrochloride
    		Inhibitor 99.41%
    GRP-60367 hydrochloride is a first-in-class small-molecule rabies virus (RABV) entry inhibitor with nanomolar potency against some RABV strains. GRP-60367 hydrochloride specifically targets the RABV G protein.
    GRP-60367 hydrochloride
  • HY-P5623A
    RVG-Cys
    		99.61%
    RVG-Cys (RVG29-Cys) is based on rabies virus glycoprotein (RVG29) peptide and connected to Cys to facilitate subsequent coupling.
    RVG-Cys
  • HY-P0285
    Rabies Virus Glycoprotein
    		99.69%
    Rabies Virus Glycoprotein is a 29-amino-acid cell penetrating peptide derived from a rabies virus glycoprotein that can cross the blood-brain barrier (BBB) and enter brain cells.
    Rabies Virus Glycoprotein
  • HY-P0285A
    Rabies Virus Glycoprotein TFA
    		98.32%
    Rabies Virus Glycoprotein (TFA) is a 29-amino-acid cell penetrating peptide derived from a rabies virus glycoprotein that can cross the blood-brain barrier (BBB) and enter brain cells.
    Rabies Virus Glycoprotein TFA
  • HY-P99624
    Foravirumab
    Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III.
    Foravirumab
  • HY-P99811
    Rafivirumab
    		Inhibitor
    Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails.
    Rafivirumab
  • HY-133735
    GRP-60367
    		Inhibitor
    GRP-60367 is a first-in-class small-molecule rabies virus (RABV) entry inhibitor with nanomolar potency against some RABV strains.
    GRP-60367
  • HY-P99856
    Docaravimab
    		Inhibitor
    Docaravimab is an antibody, targeting ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-III. Docaravimab can be used in research of Rabies.
    Docaravimab
  • HY-P99513
    Zamerovimab
    Zamerovimab (CTB011; SYN023) is a mixture of human monoclonal antibodies consisting of CTB011 and CTB012. Zamerovimab binds to non-overlapping epitopes on rabies virus (RABV) glycoprotein, where CTB011 binds to antigenic site III. Zamerovimab can be used in rabies studies.
    Zamerovimab
  • HY-P99727
    Mazorelvimab
    		Inhibitor
    Mazorelvimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies.
    Mazorelvimab
  • HY-P99792
    Ormutivimab
    Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model.
    Ormutivimab